{"id":"NCT00962104","sponsor":"Eli Lilly and Company","briefTitle":"Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder","officialTitle":"A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2009-08-19","resultsPosted":"2012-09-11","lastUpdate":"2012-09-11"},"enrollment":391,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Atomoxetine","otherNames":["LY139603"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).","primaryOutcome":{"measure":"Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score up to 10 Weeks","timeFrame":"Baseline, up to 10 weeks","effectByArm":[{"arm":"Atomoxetine","deltaMin":-14.3,"sd":10.4},{"arm":"Placebo","deltaMin":-8.8,"sd":9.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":24,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":["13638508","3625186","25019647"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":193},"commonTop":["Nausea","Somnolence","Decreased appetite","Headache","Nasopharyngitis"]}}